As TP53 was found to be co-mutated with PTPRD, and EGFR, KRAS were two common mutations in lung adenocarcinoma and found to have great influences on responses to ICIs, we calculated PTPRD phosphatase-mut predictive efficiency in the TP53/EGFR/KRAS mutation/WT subgroups in different cohorts. The gene discussed is KRAS; the disease is lung adenocarcinoma.